Late	late	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
after	after	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
a	a	O	O	O	O
malignant	malignant	O	O	O	O
bone	bone	O	O	OTHERS	I
tumor	tumor	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Cardiac	cardiac	O	O	O	O
function	function	O	O	O	O
was	was	O	O	O	O
assessed	assessed	O	O	O	O
in	in	O	O	O	O
long-term	long-term	O	O	O	O
survivors	survivors	O	O	O	O
of	of	O	O	O	O
malignant	malignant	O	O	O	O
bone	bone	O	O	OTHERS	I
tumors	tumors	O	DISEASE	OTHERS	I
who	who	O	O	O	O
were	were	O	O	O	O
treated	treated	O	O	O	O
according	according	O	O	O	O
to	to	O	O	O	O
Rosen	rosen	O	O	OTHERS	I
's	's	O	O	OTHERS	I
T5	t5	O	O	OTHERS	I
or	or	O	O	OTHERS	I
T10	t10	O	O	OTHERS	I
protocol	protocol	O	O	OTHERS	I
,	,	O	O	O	O
both	both	O	O	O	O
including	including	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Thirty-one	thirty-one	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
age	age	O	O	O	O
10	10	O	O	O	O
-	-	O	O	O	O
45	45	O	O	O	O
years	years	O	O	O	O
(	(	O	O	O	O
median	median	O	O	O	O
age	age	O	O	O	O
17.8	17.8	O	O	O	O
years	years	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
2.3	2.3	O	O	O	O
-	-	O	O	O	O
14.1	14.1	O	O	O	O
years	years	O	O	O	O
(	(	O	O	O	O
median	median	O	O	O	O
8.9	8.9	O	O	O	O
years	years	O	O	O	O
)	)	O	O	O	O
following	following	O	O	O	O
completion	completion	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Cumulative	cumulative	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
225	225	O	O	O	O
-	-	O	O	O	O
550	550	O	O	O	O
mg/m2	mg/m2	O	O	O	O
(	(	O	O	O	O
median	median	O	O	O	O
dose	dose	O	O	O	O
360	360	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
evaluation	evaluation	O	O	O	O
consisted	consisted	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
history	history	O	O	O	O
,	,	O	O	O	O
physical	physical	O	O	O	O
examination	examination	O	O	O	O
,	,	O	O	O	O
electrocardiogram	electrocardiogram	O	O	O	O
(	(	O	O	O	O
ECG	ecg	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
signal	signal	O	O	O	O
averaged	averaged	O	O	O	O
ECG	ecg	O	O	O	O
,	,	O	O	O	O
24-hour	24-hour	O	O	O	O
ambulatory	ambulatory	O	O	O	O
ECG	ecg	O	O	O	O
,	,	O	O	O	O
echocardiography	echocardiography	O	O	O	O
and	and	O	O	O	O
radionuclide	radionuclide	O	O	O	O
angiography	angiography	O	O	O	O
.	.	O	O	O	O

Eighteen	eighteen	O	O	O	O
of	of	O	O	O	O
31	31	O	O	O	O
(	(	O	O	O	O
58	58	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
showed	showed	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
defined	defined	O	O	O	O
as	as	O	O	O	O
having	having	O	O	O	O
one	one	O	O	O	O
or	or	O	O	O	O
more	more	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
following	following	O	O	O	O
abnormalities	abnormalities	O	O	O	O
:	:	O	O	O	O
late	late	O	O	O	O
potentials	potentials	O	O	O	O
,	,	O	O	O	O
complex	complex	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
arrhythmias	arrhythmias	O	DISEASE	OTHERS	I
,	,	O	O	O	O
left	left	O	O	O	O
ventricular	ventricular	O	O	OTHERS	I
dilation	dilation	O	O	OTHERS	I
,	,	O	O	O	O
decreased	decreased	O	O	O	O
shortening	shortening	O	O	O	O
fraction	fraction	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
decreased	decreased	O	O	O	O
ejection	ejection	O	O	O	O
fraction	fraction	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
cardiac	cardiac	O	O	OTHERS	I
abnormalities	abnormalities	O	O	OTHERS	I
increased	increased	O	O	O	O
with	with	O	O	O	O
length	length	O	O	O	O
of	of	O	O	O	O
follow-up	follow-up	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
.05	.05	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
correlation	correlation	O	O	O	O
could	could	O	O	O	O
be	be	O	O	O	O
demonstrated	demonstrated	O	O	O	O
between	between	O	O	O	O
cumulative	cumulative	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
cardiac	cardiac	O	O	O	O
status	status	O	O	O	O
,	,	O	O	O	O
except	except	O	O	O	O
for	for	O	O	O	O
heart	heart	O	O	O	O
rate	rate	O	O	O	O
variability	variability	O	O	O	O
.	.	O	O	O	O

When	when	O	O	O	O
adjusted	adjusted	O	O	O	O
to	to	O	O	O	O
body	body	O	O	O	O
surface	surface	O	O	O	O
area	area	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
left	left	O	O	O	O
ventricular	ventricular	O	O	O	O
posterior	posterior	O	O	O	O
wall	wall	O	O	O	O
thickness	thickness	O	O	O	O
(	(	O	O	O	O
LVPW	lvpw	O	O	O	O
index	index	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
decreased	decreased	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
doxorubicin-induced	doxorubicin-induced	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
high	high	O	O	O	O
and	and	O	O	O	O
increases	increases	O	O	O	O
with	with	O	O	O	O
follow-up	follow-up	O	O	O	O
,	,	O	O	O	O
irrespective	irrespective	O	O	O	O
of	of	O	O	O	O
cumulative	cumulative	O	O	O	O
dose	dose	O	O	O	O
.	.	O	O	O	O

Life-long	life-long	O	O	O	O
cardiac	cardiac	O	O	O	O
follow-up	follow-up	O	O	O	O
in	in	O	O	O	O
these	these	O	O	O	O
patients	patients	O	O	O	O
is	is	O	O	O	O
warranted	warranted	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
our	our	O	O	O	O
study	study	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
heart	heart	O	O	O	O
rate	rate	O	O	O	O
variability	variability	O	O	O	O
and	and	O	O	O	O
LVPW	lvpw	O	O	O	O
index	index	O	O	O	O
could	could	O	O	O	O
be	be	O	O	O	O
sensitive	sensitive	O	O	O	O
indicators	indicators	O	O	O	O
for	for	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

